These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Trial of Nemolizumab in Moderate-to-Severe Prurigo Nodularis. Ständer S; Yosipovitch G; Legat FJ; Lacour JP; Paul C; Narbutt J; Bieber T; Misery L; Wollenberg A; Reich A; Ahmad F; Piketty C N Engl J Med; 2020 Feb; 382(8):706-716. PubMed ID: 32074418 [TBL] [Abstract][Full Text] [Related]
4. Phase 3 Trial of Nemolizumab in Patients with Prurigo Nodularis. Kwatra SG; Yosipovitch G; Legat FJ; Reich A; Paul C; Simon D; Naldi L; Lynde C; De Bruin-Weller MS; Nahm WK; Sauder M; Gharib R; Barbarot S; Szepietowski JC; Conrad C; Fleischer A; Laquer VT; Misery L; Serra-Baldrich E; Lapeere H; Ahmad F; Jabbar Lopez ZK; Piketty C; Ständer S; N Engl J Med; 2023 Oct; 389(17):1579-1589. PubMed ID: 37888917 [TBL] [Abstract][Full Text] [Related]
5. Nemolizumab efficacy in prurigo nodularis: onset of action on itch and sleep disturbances. Ständer S; Yosipovitch G; Lacour JP; Legat FJ; Paul C; Reich A; Chaouche K; Ahmad F; Piketty C J Eur Acad Dermatol Venereol; 2022 Oct; 36(10):1820-1825. PubMed ID: 35766128 [TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of nemolizumab in paediatric patients aged 6-12 years with atopic dermatitis with moderate-to-severe pruritus: results from a phase III, randomized, double-blind, placebo-controlled, multicentre study. Igarashi A; Katsunuma T; Matsumura T; Komazaki H; Br J Dermatol; 2023 Dec; 190(1):20-28. PubMed ID: 37522351 [TBL] [Abstract][Full Text] [Related]
7. Trial of Nemolizumab and Topical Agents for Atopic Dermatitis with Pruritus. Kabashima K; Matsumura T; Komazaki H; Kawashima M; N Engl J Med; 2020 Jul; 383(2):141-150. PubMed ID: 32640132 [TBL] [Abstract][Full Text] [Related]
8. Modulation of Neuroimmune and Epithelial Dysregulation in Patients With Moderate to Severe Prurigo Nodularis Treated With Nemolizumab. Deng J; Liao V; Parthasarathy V; Cornman HL; Kambala A; Kwatra MM; Ständer S; Piketty C; Chaskar P; Krishnaswamy JK; Julia V; Kwatra SG JAMA Dermatol; 2023 Sep; 159(9):977-985. PubMed ID: 37556125 [TBL] [Abstract][Full Text] [Related]
9. Validation of the Peak Pruritus Numerical Rating Scale as a Patient-Reported Outcome Measure in Prurigo Nodularis. Kwatra SG; Rodriguez D; Dias-Barbosa C; Budhiarso I; Fofana F; Vernon M; Gabriel S; Piketty C; Puelles J Dermatol Ther (Heidelb); 2023 Oct; 13(10):2403-2416. PubMed ID: 37615836 [TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of vixarelimab, a human monoclonal oncostatin M receptor β antibody, in moderate-to-severe prurigo nodularis: a randomised, double-blind, placebo-controlled, phase 2a study. Sofen H; Bissonnette R; Yosipovitch G; Silverberg JI; Tyring S; Loo WJ; Zook M; Lee M; Zou L; Jiang GL; Paolini JF EClinicalMedicine; 2023 Mar; 57():101826. PubMed ID: 36816342 [TBL] [Abstract][Full Text] [Related]
11. Efficacy and Safety of Abrocitinib in Prurigo Nodularis and Chronic Pruritus of Unknown Origin: A Nonrandomized Controlled Trial. Kwatra SG; Bordeaux ZA; Parthasarathy V; Kollhoff AL; Alajmi A; Pritchard T; Cornman HL; Kambala A; Lee KK; Manjunath J; Ma EZ; Dillen C; Kwatra MM JAMA Dermatol; 2024 Jul; 160(7):717-724. PubMed ID: 38837144 [TBL] [Abstract][Full Text] [Related]
12. Validation of Psychometric Properties of the Itch Numeric Rating Scale for Pruritus Associated With Prurigo Nodularis: A Secondary Analysis of a Randomized Clinical Trial. Kimel M; Zeidler C; Kwon P; Revicki D; Ständer S JAMA Dermatol; 2020 Dec; 156(12):1354-1358. PubMed ID: 32936233 [TBL] [Abstract][Full Text] [Related]
13. Phase 2B randomized study of nemolizumab in adults with moderate-to-severe atopic dermatitis and severe pruritus. Silverberg JI; Pinter A; Pulka G; Poulin Y; Bouaziz JD; Wollenberg A; Murrell DF; Alexis A; Lindsey L; Ahmad F; Piketty C; Clucas A J Allergy Clin Immunol; 2020 Jan; 145(1):173-182. PubMed ID: 31449914 [TBL] [Abstract][Full Text] [Related]
14. The Sleep Disturbance Numerical Rating Scale: Content Validity, Psychometric Validation, and Meaningful Within-Patient Change in Prurigo Nodularis. Ständer S; Fofana F; Dias-Barbosa C; Rodriguez D; Budhiarso I; Jabbar-Lopez ZK; Piketty C; Vernon M; Puelles J Dermatol Ther (Heidelb); 2023 Jul; 13(7):1587-1602. PubMed ID: 37329468 [TBL] [Abstract][Full Text] [Related]
15. A systematic review of interleukin-31 inhibitors in the treatment of prurigo nodularis. Nilforoushzadeh MA; Heidari N; Ghane Y; Heidari A; Hajikarim-Hamedani A; Hosseini S; Jaffary F; Najar Nobari M; Tavakolzadeh P; Najar Nobari N Inflammopharmacology; 2024 Apr; 32(2):991-1003. PubMed ID: 38332383 [TBL] [Abstract][Full Text] [Related]
16. Prurigo nodularis: new insights into pathogenesis and novel therapeutics. Liao V; Cornman HL; Ma E; Kwatra SG Br J Dermatol; 2024 May; 190(6):798-810. PubMed ID: 38345154 [TBL] [Abstract][Full Text] [Related]
17. Anti-pruritic effect of nemolizumab in hemodialysis patients with uremic pruritus: a phase II, randomized, double-blind, placebo-controlled clinical study. Kinugasa E; Igawa K; Shimada H; Kondo M; Funakoshi S; Imada N; Itami N; Fukazawa N; Takubo R; Kawata Y; Murota H Clin Exp Nephrol; 2021 Aug; 25(8):875-884. PubMed ID: 33754202 [TBL] [Abstract][Full Text] [Related]
18. A critical evaluation of nemolizumab for prurigo nodularis. Brooks SG; Yosipovitch G Expert Rev Clin Immunol; 2024 Jun; 20(6):577-587. PubMed ID: 38217530 [TBL] [Abstract][Full Text] [Related]
19. Efficacy and Safety of Abrocitinib in Patients with Severe and/or Difficult-to-Treat Atopic Dermatitis: A Post Hoc Analysis of the Randomized Phase 3 JADE COMPARE Trial. Simpson EL; Silverberg JI; Thyssen JP; Viguier M; Thaçi D; de Bruin-Weller M; Weidinger S; Chan G; DiBonaventura M; Biswas P; Feeney C; Koulias C; Cork MJ Am J Clin Dermatol; 2023 Jul; 24(4):609-621. PubMed ID: 37213005 [TBL] [Abstract][Full Text] [Related]
20. Dupilumab in patients with prurigo nodularis: two randomized, double-blind, placebo-controlled phase 3 trials. Yosipovitch G; Mollanazar N; Ständer S; Kwatra SG; Kim BS; Laws E; Mannent LP; Amin N; Akinlade B; Staudinger HW; Patel N; Yancopoulos GD; Weinreich DM; Wang S; Shi G; Bansal A; O'Malley JT Nat Med; 2023 May; 29(5):1180-1190. PubMed ID: 37142763 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]